Higher Revenue Through Growth and Expansion of Emerging Businesses
First written in FY2019. 10 of 13 entries say "Restated". Latest entry: FY2025.
Vital Ksk Holdings moved to the "Worse" side of this theme in 2025, 1 year after the typical company in this theme (2024).
12 other companies' latest entry also says "Reframed".
- FY2025ReframedAnnual report
「The medium-term vision of Medium-Term Management Plan 2027 is “Innovation in business models with an eye to the next generation—Phase 2—.”」
The company has shifted from the Fourth Medium-Term Management Plan's focus on the growth and expansion of emerging businesses to Phase 2 of business model innovation, including business portfolio management, financial strategy and growth investment. - FY2022ReframedAnnual report
「Under the Fifth Medium-Term Management Plan, we will pursue innovation in business models with an eye to the next generation as our medium-term vision.」
The plan's wording has shifted from “increasing revenue through the growth and expansion of emerging businesses” under the Fourth Medium-Term Management Plan to “innovation in business models with an eye to the next generation.” - FY2022-Q3RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*)”; and “3. Strengthening the group management structure.”」
Even in the final year of the Fourth Medium-Term Management Plan, the company continues to set out increased revenue through the growth and expansion of emerging businesses. - FY2022-Q2RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*)”; and “3. Strengthening the group management structure.”」
Even in the final year of the Fourth Medium-Term Management Plan, the company continues to set out increased revenue through the growth and expansion of emerging businesses. - FY2022-Q1RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*)”; and “3. Strengthening the group management structure.”」
Even in the final year of the Fourth Medium-Term Management Plan, the company continues to set out increased revenue through the growth and expansion of emerging businesses. - FY2021-Q3RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*)”; and “3. Strengthening the group management structure.”」
The company has reaffirmed increased revenue through the growth and expansion of emerging businesses as a practical initiative under the Fourth Medium-Term Management Plan. - FY2021-Q2RestatedAnnual report
「“2. Increasing revenue through the growth and expansion of emerging businesses (*)”」
The company continues to pursue increased revenue through the growth and expansion of emerging businesses as a practical initiative under the Fourth Medium-Term Management Plan. - FY2021-Q1RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*)”; and “3. Strengthening the group management structure.”」
The company has reaffirmed increased revenue through the growth and expansion of emerging businesses as a practical initiative under the Fourth Medium-Term Management Plan. - FY2020RestatedAnnual report
「2. Increasing revenue through the growth and expansion of emerging businesses (*3)」
The company continues to pursue increased revenue through the growth and expansion of emerging businesses as a target of the Fourth Medium-Term Management Plan. - FY2020-Q3RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*1)”; and “3. Strengthening the group management structure.”」
The company has reaffirmed increased revenue through the growth and expansion of emerging businesses as a practical initiative under the Fourth Medium-Term Management Plan. - FY2020-Q2RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*1)”; and “3. Strengthening the group management structure.”」
The company has reaffirmed increased revenue through the growth and expansion of emerging businesses as a practical initiative under the Fourth Medium-Term Management Plan. - FY2020-Q1RestatedAnnual report
「“2. Increasing revenue through the growth and expansion of emerging businesses (*1)”」
The company continues to pursue increased revenue through the growth and expansion of emerging businesses as a practical initiative under the Fourth Medium-Term Management Plan. - FY2019First statedAnnual report
「2. Increasing revenue through the growth and expansion of emerging businesses (*3)」
The Fourth Medium-Term Management Plan sets a target of growing and expanding emerging businesses outside the prescription pharmaceutical wholesaling business and increasing revenue.